SNDX241220C20000
- 0.10
- 0.000.00%
Syndax Pharmaceuticals Newsroom
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $33
Barclays Gives a Buy Rating to Syndax Pharmaceuticals (SNDX)
Trending Stocks Today | Micron Technology Falls 14.29% Post-Market
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $39
J.P. Morgan Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
Express News | Syndax Pharmaceuticals Inc : JP Morgan Raises Target Price to $39 From $38
Trending Stocks Today | U-BX Technology Surges 55.86% Post-Market
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $42 to $51
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $25 to $51
Syndax Pharmaceuticals (SNDX) Receives a Buy From Stifel Nicolaus
Syndax Pharmaceuticals (SNDX) Gets a Buy From TD Cowen
While Syndax Pharmaceuticals (NASDAQ:SNDX) Shareholders Have Made 85% in 5 Years, Increasing Losses Might Now Be Front of Mind as Stock Sheds 6.8% This Week
Syndax Pharmaceuticals Price Target Maintained With a $51.00/Share by HC Wainwright & Co.
Syndax Pharmaceuticals Analyst Ratings
Edward White Issues Buy Rating for Syndax Pharmaceuticals Due to Promising Revuforj Data and Market Potential
Barclays Releases a Buy Rating on Syndax Pharmaceuticals (SNDX)
Analysts Conflicted on These Healthcare Names: Revance Therapeutics (RVNC), Syndax Pharmaceuticals (SNDX) and Align Tech (ALGN)
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), UnitedHealth (UNH) and Disc Medicine (IRON)
Syndax Announces Additional Data From AUGMENT-101 Trial Of Revuforj
Express News | Syndax Pharmaceuticals Inc -Plans to Initiate Pivotal Trial With This Combination in Front-Line Newly Diagnosed Patients by Year-End 2024